PFIZER INC (PFE)       49.71  -1.02 (-2.01%)

49.71  -1.02 (-2.01%)

US7170811035 - Common Stock - After market: 49.81 +0.1 (+0.2%)


Fundamental Rating

6

Taking everything into account, PFE scores 6 out of 10 in our fundamental rating. PFE was compared to 257 industry peers in the Pharmaceuticals industry. While PFE has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on PFE.




Profitability

Profitability Rating

8

PFE has a Return On Assets of 15.24%. This is amongst the best returns in the industry. The industry average is -41.45%. PFE outperforms 94% of its industry peers.
PFE's Return On Equity of 32.14% is amongst the best of the industry. PFE does better than the industry average Return On Equity of 20.44%.

PFE has a Profit Margin of 29.87%. This is amongst the best returns in the industry. The industry average is -108.01%. PFE outperforms 94% of its industry peers.
The Piotroski-F score of PFE is 7.00. This is a strong score and indicates good health and profitability for PFE.
VS Industry

ROA (15.24%) VS Industry: 94% outperformed.

-1,292.14
111.39

ROE (32.14%) VS Industry: 67% outperformed.

1.38
176.97

Profit Margin (29.87%) VS Industry: 94% outperformed.

-53,337.68
1,968.82

Valuation

Valuation Rating

7

With a Price/Earnings Ratio of 7.57, the valuation of PFE can be described as very cheap.
PFE's Price/Earning Ratio is a bit cheaper than the industry average which is at 14.22.
The Forward Price/Earnings Ratio of 9.43 indicates a rather cheap valuation of PFE.
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

When comparing the current price to the book value of PFE, we can conclude it is valued correctly. It is trading at 3.01 times its book value.
When comparing the Enterprise Value to EBITDA ratio of PFE to the average industry ratio of 2.93, PFE is valued in line with its industry peers.
When comparing the price book ratio of PFE to the average industry price book ratio of 1.46, PFE is valued more expensive than its industry peers.
VS Industry

Price/Earnings (7.57) VS Industry: 73% outperformed.

86.15
0.67

Price/Book (3.01) VS Industry: 28% outperformed.

305.58
0.10

Enterprise Value/ EBITDA (5.88) VS Industry: 41% outperformed.

233.81
0.00

Growth

Growth Rating

4

PFE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 74.73%, which is quite impressive.
The Earnings Per Share has been growing by 13.08% on average over the past 5 years. This is quite good.
The Revenue has grown by 44.04% in the past year. This is a very strong growth!
PFE is expected to show a decrease in Earnings Per Share. In the coming 5 years, the EPS will decrease by -7.15% yearly.

Measured over the past 5 years, PFE shows a small growth in Revenue. The Revenue has been growing by 9.00% on average per year.
Based on estimates for the next 5 years, PFE will show a decrease in Revenue. The Revenue will decrease by -9.93% on average per year.
When comparing the EPS growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS13.08% 13.79% 74.73% 46.58% 9.21% 0.35% -7.15%
Revenue9% 25.81% 44.04% 21.75% -1.55% -5.17% -9.93%

Health

Health Rating

5

PFE has an Altman-Z score of 3.86. This indicates that PFE is financially healthy and little risk of bankruptcy at the moment.
When comparing the Altman-Z score to an average industry score of -0.53, PFE is in better financial health than the average industry peer.
PFE has a good Piotroski-F score of 7.00. This indicates a good health and good profitability for PFE.
PFE has a Current Ratio of 1.59. This is a normal value and indicates that PFE is financially healthy and should not expect problems in meeting its short term obligations.

PFE has a Quick Ratio of 1.37. This is a normal value and indicates that PFE is financially healthy and should not expect problems in meeting its short term obligations.
When comparing the Current Ratio of PFE to the average industry Current Ratio of 3.51, PFE is less able to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 2.88, PFE is worse placed to pay its short term obligations than its industry peers.
When comparing the Debt to Equity Ratio of PFE to the average industry Debt to Equity Ratio of 0.00, PFE required more debt to finance its operations than its industry peers.
VS Industry

Debt/Equity (0.35) VS Industry: 29% outperformed.

59.36
0.00

Quick Ratio (1.37) VS Industry: 26% outperformed.

-2.73
76.82

Current Ratio (1.59) VS Industry: 23% outperformed.

0.09
76.82

Altman-Z (3.86) VS Industry: 77% outperformed.

-236.92
114.17

Dividend

Dividend Rating

7

PFE's Dividend Yield is a higher than the industry average which is at 2.73.
Compared to an average S&P500 Dividend Yield of 2.43, PFE pays a bit more dividend than the S&P500 average.
PFE's earnings are growing more than its dividend. This makes the dividend growth sustainable.
PFE pays out 29.99% of its income as dividend. This is a sustainable payout ratio.

PFE has paid a dividend for at least 10 years, which is a reliable track record.
PFE has a Yearly Dividend Yield of 3.25%. Purely for dividend investing, there may be better candidates out there.
The dividend of PFE has a limited annual growth rate of 4.68%.
VS Industry

Dividend Yield (3.25%) VS Industry: 61% outperformed.

0.67
7.18
PFE Daily chart

PFIZER INC49.71

NYSE:PFE (12/6/2022, 3:43:30 PM)-1.02 (-2.01%)

After market: 49.81 +0.1 (+0.2%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Pharmaceuticals
Earnings (Last) 11-01 2022-11-01/bmo Earnings (Next) 02-06 2023-02-06
Ins Owners 0.04% Inst Owners 69.24%
Market Cap 279.04B Analysts 75
Valuation
PE 7.57 Fwd PE 9.43
PEG (NY) 0.16 PEG (5Y) 0.58
P/S 2.8 P/B 3.01
EV/EBITDA 5.88
Dividend
Dividend Yield 3.25% Dividend Growth 4.68%
DP 29.99% Ex-Date 11-03 2022-11-03 (0.4)
Growth
EPS 1Y 74.73% EPS 3Y 13.79%
EPS 5Y 13.08% EPS growth Q2Q 32.84%
EPS Next Y 46.58% EPS Next 2Y 9.21%
EPS Next 3Y 0.35% EPS Next 5Y -7.15%
Revenue growth 1Y 44.04% Revenue growth 3Y 25.81%
Revenue growth 5Y 9% Revenue growth Q2Q -5.81%
Revenue Next Year 21.75% Revenue Next 2Y -1.55%
Revenue Next 3Y -5.17% Revenue Next 5Y -9.93%
Health
Current Ratio 1.59 Quick Ratio 1.37
Altman-Z 3.86 F-Score 7
Debt/Equity 0.35 WACC 8.46%
ROIC/WACC 10.68
Profitability
ROA 15.24% ROE 32.14%
ROICexgc 90.33% ROIC 22.98%
PM 29.87% OM 37.8%
Asset Turnover 0.51

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA